Free Trial
→ $0. Later: $29.97. (From Profits Run) (Ad)tc pixel
NASDAQ:HOWL

Werewolf Therapeutics Q3 2026 Earnings Date & Estimates

Werewolf Therapeutics logo
$1.00 +0.02 (+1.73%)
As of 12:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Werewolf Therapeutics is estimated to report Q3 2026 earnings on Friday, November 13, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Werewolf Therapeutics in Q3 2026

Werewolf Therapeutics is expected to post earnings of -$0.22 per share on revenue of $18.31 million. In the same quarter a year earlier Werewolf Therapeutics reported -$0.36 per share. Werewolf Therapeutics last reported on July 31, 2026, posting $0.08 per share and beating the -$0.28 consensus estimate. Werewolf Therapeutics has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.22
Expected Revenue
$18.31 million
Prior-Year EPS
-$0.36

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.08 (Beat by +$0.36)
Last Quarter Revenue
$21 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Werewolf Therapeutics Q3 2026 Earnings FAQ

Werewolf Therapeutics (NASDAQ:HOWL) is estimated to report Q3 2026 earnings on Friday, November 13, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Werewolf Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 20, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Werewolf Therapeutics to post earnings of -$0.22 per share for Q3 2026.

The consensus revenue estimate for Werewolf Therapeutics is $18.31 million for Q3 2026.

Werewolf Therapeutics Earnings Headlines

Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
November 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/werewolf-therapeutics-clinical-data-wtx-133000170.html
Werewolf Therapeutics' Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting
November 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/09/3398415/0/en/werewolf-therapeutics-clinical-data-for-wtx-124-and-wtx-330-presented-at-the-society-for-immunotherapy-of-cancer-s-sitc-2026-annual-meeting.html
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
November 13 at 1:00 AM  |  Base Camp Trading (Ad)
Werewolf Therapeutics (HOWL) Set to Announce Earnings on Tuesday
November 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31173089
Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
October 30, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancer-s-sitc-2026-annual-meeting-1036692130
Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting
October 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/30/3392204/0/en/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancer-s-sitc-2026-annual-meeting.html
See More Werewolf Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Werewolf Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Werewolf Therapeutics and other key companies, straight to your email.

About Werewolf Therapeutics

Werewolf Therapeutics (NASDAQ:HOWL) is a clinical-stage biotechnology company focused on developing cancer treatments that stimulate the immune system. The company’s approach is designed to activate immune responses within the tumor microenvironment while limiting exposure to healthy tissues.

Werewolf’s technology platform, known as INDUKINE, uses conditionally activated cytokines. These therapeutic proteins are intended to remain inactive in the bloodstream and become activated primarily in tumors, where they may help recruit and enhance immune cells to attack cancer. The company has developed investigational programs based on cytokines including interleukin-2, interleukin-12 and interleukin-18.

The company’s pipeline has included WTX-124, an investigational, tumor-activated interleukin-2 therapy, and WTX-330, an investigational interleukin-12 program. These candidates have been evaluated in clinical studies for patients with advanced or metastatic solid tumors. Werewolf Therapeutics was founded in 2017 and is headquartered in Waltham, Massachusetts.

View Werewolf Therapeutics Profile
Earnings Tools